Royalty Pharma plc (RPRX) reports Q3 results; Offers Guidance
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $58.29 +1.11%
Financial Fact:
Total revenues and other income: 10K
Today's EPS Names:
OCCI, IPX, ALZN, More
Financial Fact:
Total revenues and other income: 10K
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q3 resutls. Revenue for the quarter came in at $573 million versus the consensus estimate of $584.92 million.
GUIDANCE:
Adjusted Cash Receipts expected to be $2,750 to $2,800 million, which includes $458m from the acceleration of payments related to Pfizer’s acquisition of Biohaven.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and memory not a classic bubble, but future returns uncertain - strategist
- Darden Restaurants falls as Q1 revenue misses expectations
- Needham remains cautious on Nike stock, sees more downside risk
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
